Immuno'line™ technologies can be applied to map, identify, characterise and engineer T-cell epitopes, i.e. the parts of a protein that are responsible for immunogenicity.
When a protein is found to induce an immune response, the precise portion that is responsible for immunogenicity can be identified using Immuno'Line™ technologies.
Overlapping peptides covering the sequence of the protein of interest are used. The first step to identification of immunodominant epitopes consists in evaluating the capacity of each individual peptide to trigger specific T-cell activation.
If immunodominant peptides are identified, these can be further characterised using HLA binding assays: the affinity of each immunodominant peptide for individual HLA class II molecules from our collection in measured using CEA's automated platform. This analysis provides additional information on the residues that are involved in immunogenicity, thus opening the way to engineer your biologics.
After characterising the immunogenic T-epitopes, Protéus brings an exceptional blend of know-how and technologies for engineering variants with customised immunogenicity:
- Vaccines with enhanced T-cell immunogenicity
- Therapeutic proteins with low or no immunogenicity
Please contact us to discuss your project and build a custom strategy.